0
     

Report Added
Report already added
Autism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Autism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Autism - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Autism (Central Nervous System) pipeline landscape.

Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include child’s sex, family history, fragile X syndrome, Tourette syndrome and epilepsy. Treatment includes SSRIs (selective serotonin reuptake inhibitors), antidepressants, antipsychotics, and sedatives.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Autism - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Autism (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Autism (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Autism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 6, 6, 26, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Autism (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Autism (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Autism (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Autism (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Autism (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Autism (Central Nervous System)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Autism (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Autism (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Autism - Overview
Autism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Autism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Autism - Companies Involved in Therapeutics Development
4D Pharma Plc
AgeneBio Inc
AgoneX Biopharmaceuticals Inc
Allos Pharma Inc
AsiaBiome
Axial Therapeutics Inc
Cennerv Pharma (S) Pte Ltd
ChunLab Inc
Cognosetta Inc
Curemark LLC
Enterin Inc
Epigen Biosciences Inc
EuMentis Therapeutics Inc
Herophilus
Hopstem Biotechnology LLC
iCELL Biotechnology Co Ltd
ImmunoBiome Inc
Immuron Ltd
Intra-Cellular Therapies Inc
Intrinsic Medicine Inc
Johnson & Johnson
Kuzani Pharmaceuticals Inc
MD Healthcare Inc
Omeros Corp
OptiNose Inc
Oryzon Genomics SA
Palisades Therapeutics
Panorama Researchama Research
Park Active Molecules
Reviva Pharmaceuticals Inc
Richter Gedeon Nyrt
RogCon Inc
Rugen Therapeutics R&D (Shanghai) Co Ltd
Scioto Biosciences Inc
SciSparc Ltd
Sengenics Corp Pte Ltd
Standigm Inc
Stem Cell Medicine Ltd
Sumitomo Dainippon Pharma Co Ltd
Tempero Bio
The Greater Cannabis Company Inc
Vanda Pharmaceuticals Inc
Yamo Pharmaceuticals LLC
Zelira Therapeutics Ltd
Autism - Drug Profiles
(cannabidiol + dronabinol) sublingual - Drug Profile
Product Description
Mechanism Of Action
(cannabidiol + palmidrol) - Drug Profile
Product Description
Mechanism Of Action
AB-05 - Drug Profile
Product Description
Mechanism Of Action
AB-2004 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AGB-473 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Antibodies for Autism - Drug Profile
Product Description
Mechanism Of Action
arbaclofen - Drug Profile
Product Description
Mechanism Of Action
ARN-23746 - Drug Profile
Product Description
Mechanism Of Action
Biologic for Autism - Drug Profile
Product Description
Mechanism Of Action
Biologics for Autism - Drug Profile
Product Description
Mechanism Of Action
History of Events
Biologics for Autism - Drug Profile
Product Description
Mechanism Of Action
brilaroxazine - Drug Profile
Product Description
Mechanism Of Action
cariprazine - Drug Profile
Product Description
Mechanism Of Action
History of Events
CB-0306 - Drug Profile
Product Description
Mechanism Of Action
CLP-301 - Drug Profile
Product Description
Mechanism Of Action
CM-AT - Drug Profile
Product Description
Mechanism Of Action
History of Events
CS-0022 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Drug for Autism and Dementia - Drug Profile
Product Description
Mechanism Of Action
Drugs for Autism - Drug Profile
Product Description
Mechanism Of Action
EM-036 - Drug Profile
Product Description
Mechanism Of Action
ENT-01 - Drug Profile
Product Description
Mechanism Of Action
EPGN-1370 - Drug Profile
Product Description
Mechanism Of Action
History of Events
histamine dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
hNPC-EX - Drug Profile
Product Description
Mechanism Of Action
HTL-0014242 - Drug Profile
Product Description
Mechanism Of Action
History of Events
IMB-002 - Drug Profile
Product Description
Mechanism Of Action
IMM-124E - Drug Profile
Product Description
Mechanism Of Action
History of Events
JNJ-5279 - Drug Profile
Product Description
Mechanism Of Action
History of Events
lurasidone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
MDH-001 - Drug Profile
Product Description
Mechanism Of Action
MDH-101 - Drug Profile
Product Description
Mechanism Of Action
MDH-204 - Drug Profile
Product Description
Mechanism Of Action
metyrosine - Drug Profile
Product Description
Mechanism Of Action
History of Events
MRx-0006 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Neurodevelopmental Disease - Drug Profile
Product Description
Mechanism Of Action
OM-001 - Drug Profile
Product Description
Mechanism Of Action
oxytocin - Drug Profile
Product Description
Mechanism Of Action
History of Events
PAM-28 - Drug Profile
Product Description
Mechanism Of Action
RCUR-313 - Drug Profile
Product Description
Mechanism Of Action
RCUR-SMP - Drug Profile
Product Description
Mechanism Of Action
SB-121 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule for Neurolological Disorders - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Target GPR63 for Autism - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Autism - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Agonize CB1 and CB2 for CNS Diseases and Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Antagonize GRIN2B for Autism and Obsessive Compulsive Disorders - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit Casein Kinase 1 for Autism - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit PDE2 for CNS Disorders - Drug Profile
Product Description
Mechanism Of Action
Stem Cell Therapy for Asherman Syndrome, Parkinson's Disease, Bronchial Fistula, Spastic Cerebral palsy, Primary Ovarian Insufficiency, Graft versus Host Disease, Acute Renal Failure (ARF) (Acute Kidney Injury), Uveitis, Hashimoto Thyroiditis, Systemic Lupus Erythematosus and Spinal Cord Injury - Drug Profile
Product Description
Mechanism Of Action
History of Events
Stem Cell Therapy for Autism - Drug Profile
Product Description
Mechanism Of Action
History of Events
tasimelteon - Drug Profile
Product Description
Mechanism Of Action
History of Events
vafidemstat - Drug Profile
Product Description
Mechanism Of Action
History of Events
YQW-036 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Autism - Dormant Projects
Autism - Discontinued Products
Autism - Product Development Milestones
Featured News & Press Releases
Feb 14, 2022: Nature Medicine publishes full results from Axial Therapeutics’ phase 1b/2a clinical trial in Autism Spectrum Disorder (ASD)
Jan 28, 2022: Yamo Pharma doses first subject in Phase II autism spectrum disorder trial
Dec 01, 2021: Axial Therapeutics begins dosing in Phase IIb autism therapy trial
Nov 10, 2021: Yamo Pharmaceuticals receives investment from autism impact fund to support phase 2 study of L1-79 in autism spectrum disorder
Oct 27, 2021: Axial Therapeutics receives FDA clearance of IND application and initiates phase 2b trial for AB-2004, lead gut-targeted, molecular therapeutic for the treatment of irritability in autism spectrum disorder
Aug 18, 2021: Scioto Biosciences announces first patient dosed in phase Ib study in patients diagnosed with autistic disorder
Apr 06, 2021: ORYZON starts preclinical collaboration on autism with the Seaver Autism Center at Mount Sinai
Dec 03, 2020: Results from Axial Therapeutics phase 1b/2a study of AB-2004 in adolescents with autism spectrum disorder met primary endpoint and reduced irritability and other symptoms
Sep 07, 2020: Powerful drug discovery protocol for autism is accelerating the development of new treatments
Jul 10, 2020: Discovery of a novel drug candidate to develop effective treatments for brain disorders
Apr 02, 2020: Axial Biotherapeutics announces positive topline results from phase 1b/2a clinical trial of AB-2004 for the treatment of Autism Spectrum Disorder
Dec 02, 2019: Therapix Biosciences announces the continued development of THX-210 ("RESPECTRUM") cannabinoids based treatment for Autism Spectrum Disorder
Nov 18, 2019: Axial Biotherapeutics announces completion of enrollment in phase 1b/2a clinical trial evaluating AB-2004 in patients with Autism Spectrum Disorder
Oct 18, 2019: Axial Biotherapeutics presents preclinical data on microbiome-derived metabolites associated with Autism Spectrum Disorder at the Society for Neuroscience 2019 Annual Meeting
Sep 23, 2019: ORYZON presents new data on vafidemstat
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Autism, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Autism - Pipeline by 4D Pharma Plc, 2022
Autism - Pipeline by AgeneBio Inc, 2022
Autism - Pipeline by AgoneX Biopharmaceuticals Inc, 2022
Autism - Pipeline by Allos Pharma Inc, 2022
Autism - Pipeline by AsiaBiome, 2022
Autism - Pipeline by Axial Therapeutics Inc, 2022
Autism - Pipeline by Cennerv Pharma (S) Pte Ltd, 2022
Autism - Pipeline by ChunLab Inc, 2022
Autism - Pipeline by Cognosetta Inc, 2022
Autism - Pipeline by Curemark LLC, 2022
Autism - Pipeline by Enterin Inc, 2022
Autism - Pipeline by Epigen Biosciences Inc, 2022
Autism - Pipeline by EuMentis Therapeutics Inc, 2022
Autism - Pipeline by Herophilus, 2022
Autism - Pipeline by Hopstem Biotechnology LLC, 2022
Autism - Pipeline by iCELL Biotechnology Co Ltd, 2022
Autism - Pipeline by ImmunoBiome Inc, 2022
Autism - Pipeline by Immuron Ltd, 2022
Autism - Pipeline by Intra-Cellular Therapies Inc, 2022
Autism - Pipeline by Intrinsic Medicine Inc, 2022
Autism - Pipeline by Johnson & Johnson, 2022
Autism - Pipeline by Kuzani Pharmaceuticals Inc, 2022
Autism - Pipeline by MD Healthcare Inc, 2022
Autism - Pipeline by Omeros Corp, 2022
Autism - Pipeline by OptiNose Inc, 2022
Autism - Pipeline by Oryzon Genomics SA, 2022
Autism - Pipeline by Palisades Therapeutics, 2022
Autism - Pipeline by Panorama Researchama Research, 2022
Autism - Pipeline by Park Active Molecules, 2022
Autism - Pipeline by Reviva Pharmaceuticals Inc, 2022
Autism - Pipeline by Richter Gedeon Nyrt, 2022
Autism - Pipeline by RogCon Inc, 2022
Autism - Pipeline by Rugen Therapeutics R&D (Shanghai) Co Ltd, 2022
Autism - Pipeline by Scioto Biosciences Inc, 2022
Autism - Pipeline by SciSparc Ltd, 2022
Autism - Pipeline by Sengenics Corp Pte Ltd, 2022
Autism - Pipeline by Standigm Inc, 2022
Autism - Pipeline by Stem Cell Medicine Ltd, 2022
Autism - Pipeline by Sumitomo Dainippon Pharma Co Ltd, 2022
Autism - Pipeline by Tempero Bio, 2022
Autism - Pipeline by The Greater Cannabis Company Inc, 2022
Autism - Pipeline by Vanda Pharmaceuticals Inc, 2022
Autism - Pipeline by Yamo Pharmaceuticals LLC, 2022
Autism - Pipeline by Zelira Therapeutics Ltd, 2022
Autism - Dormant Projects, 2022
Autism - Dormant Projects, 2022 (Contd..1)
Autism - Discontinued Products, 2022

List of Figures
Number of Products under Development for Autism, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Report Title: Autism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW